Table 1.
Studies with available original next generation sequencing data selected for the analysis.
| Year | Author | Sequenced Samples (n) | Sample Histotype (n) | WGS (n) | WES (n) | t-NGS (n) | Genes Analyzed | Sequencing | Selected Samples (n) |
|---|---|---|---|---|---|---|---|---|---|
| 2014 | Fernandez-Cuesta et al. [11] | 44 | TC (34) | TC (24) | TC (10) | 0 | All | WGS and WES | 34 TC 5 AC |
| AC (5) | AC (1) | AC (4) | |||||||
| CA NAS (5) | CA NAS (4) | CA NAS (1) | |||||||
| 2015 | Armengol et al. [29] | 25 | TC (21) | 0 | 0 | TC (21) | 22 (t-NGS) | Ion AmpliSeq Colon and Lung Cancer Research Panel v2 (Thermofisher) | TC (21) |
| AC (4) | AC (4) | AC (4) | |||||||
| 2015 | Karlsson et al. [30] | 32 | LCNEC (32) | 0 | 0 | LCNEC (32) | 26 (t-NGS) | Illumina TruSight Tumor 26-gene next-generation sequencing (NGS) panel (Illumina). LCNEC cases were screened for retinoblastoma 1 gene (RB1) mutations by using a custom-designed bidirectional NGS panel (Illumina). | LCNEC (32) |
| 2015 | Vollbrecht et al. [31] | 70 | TC (17) | 0 | 0 | TC (17) | 48 (t-NGS) | TruSeq Amplicon–Cancer Panel (Illumina, San Diego, CA, USA) |
TC (17) |
| AC (17) | AC (17) | AC (17) | |||||||
| LCNEC (19) | LCNEC (19) | LCNEC (19) | |||||||
| SCLC (17) | SCLC (17) | SCLC (17) | |||||||
| 2015 | George et al. [13] | 110 | SCLC (110) | SCLC (110) | 0 | 0 | All | WGS | 110 SCLC |
| 2016 | Rekhtman et al. [23] | 45 | LCNEC (45) | 0 | 0 | LCNEC (45) | 241 (t-NGS) | Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) platform | 45 LCNEC |
| 2017 | Miyoshi et al. [32] | 168 | LCNEC (78) | 0 | 0 | LCNEC (78) | 244 (t-NGS) | Custom target-capturing panel (SureSelect XT custom 0.5–2.9 Mb, Agilent Technologies) containing all the coding exons of 244 genes | LCNEC (78) |
| SCLC (90) | SCLC (90) | SCLC (90) | |||||||
| 2017 | Simbolo et al. [10] | 148 | TC (53) | 0 | TC (10) | TC (43) | All (WES) | WES and Ion AmpliSeq Comprehensive Cancer Panel (ThermoFisher) | TC (23) |
| AC (35) | AC (4) | AC (31) | 418 (HCTS) * | AC (14) | |||||
| LCNEC (27) | LCNEC (3) | LCNEC (24) | 88 (t-NGS) | LCNEC (5) | |||||
| SCLC (33) | SCLC (3) | SCLC (30) | SCLC (4) | ||||||
| 2018 | Derks et al. [27] | 79 | LCNEC (79) | 0 | 0 | LCNEC (79) | 4 (t-NGS) | Qiagen GeneRead DNAseq Custom V2 Builder (TP53, RB1, STK11, and KEAP1) | LCNEC (79) |
| 2018 | Asiedu et al. [33] | 20 | TC (14) | TC (3) | TC (14) | 0 | All | WGS and WES | TC (14) |
| AC (6) | AC (2) | AC (6) | AC (6) | ||||||
| 2018 | George et al. [12] | 60 | LCNEC (60) | LCNEC (11) | LCNEC (55) | 0 | All | WGS and WES | 60 LCNEC |
| 2019 | Simbolo et al. [24] | 67 | AC (35) | 0 | 0 | AC (35) | 409 (HCTS) * | Ampliseq Transcriptome Human Gene Expression Kit (ThermoFisher); Ampliseq Comprehensive Cancer Panel (ThermoFisher) |
AC (14) HTCS AC (21) t-NGS LCNEC (14) HTCS LCNEC (18) t-NGS |
| LCNEC (32) | LCNEC (32) | 13 (t-NGS) | |||||||
| 2019 | Saurabh V. Laddha et al. [34] | 29 | TC (16) AC (13) |
0 | 0 | TC (16) AC (13) |
354 (t-NGS) | MSK-IMPACT | TC (16) AC (13) |
* = high-coverage targeted sequencing.